Resveratrol, obesity and diabetes

European Journal of Pharmacology

Volumn 635, Issue 1-3, 2010, Pages 1-8

  Szkudelska, Katarzyna ^a   Szkudelski, Tomasz ^a  

^a POZNA UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

Diabetes; Obesity; Prevention; Resveratrol

Indexed keywords

ESTROGEN RECEPTOR; GENISTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; POTASSIUM CHANNEL; RESVERATROL; SIRTUIN 1;

ADIPOGENESIS; AGING; CALORIC RESTRICTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG STRUCTURE; ENERGY METABOLISM; FATTY ACID SYNTHESIS; GENE EXPRESSION; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOLYSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE PHOSPHORYLATION; PANCREATITIS; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; DIABETES MELLITUS; HUMANS; OBESITY; STILBENES;

EID: 77952321187     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.054     Document Type: Review

References (71)

1. Ashcroft F., Rorsman P. Type 2 diabetes mellitus: not quite exciting enough?. Hum. Mol. Genet. 2004, 13(Spec No 1):R21-R31.
2. Atten M.J., Attar B.M., Milson T., Holian O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol. 2001, 62:1423-1432.
3. Atten M.J., Godoy-Romero E., Attar B.M., Milson T., Zopel M., Holian O. Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest. New Drugs 2005, 23:111-119.
4. Aubin M.C., Lajoie C., Clement R., Gosselin H., Calderone A., Perrault L.P. Female rats fed a high-fat diet were associated with vascular dysfunction and cardiac fibrosis in the absence of overt obesity and hyperlipidemia: therapeutic potential of resveratrol. J. Pharmacol. Exp. Ther. 2008, 325:961-968.
5. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., Wang Y., Raederstorff D., Morrow J.D., Leeuwenburgh C., Allison D.B., Saupe K.W., Cartee G.D., Weindruch R., Prolla T.A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PloS ONE 2008, 3:e2264.
6. Baur J.A., Pearson K.J., Price N.L., Jamieson N.L., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on high-calorie diet. Nature 2006, 444:337-342.
7. Bertelli A.A., Das D.K. Grapes, wines, resveratrol and heart health. J. Cardiovasc. Pharmacol. 2009, 54:468-476.
8. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2009, 2:409-418.
9. Bowers J.L., Tyulmenkov V.V., Jernigan S.C., Klinge C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000, 141:3657-3667.
10. Breen D.M., Sanli T., Giacca A., Tsiani E. Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun. 2008, 374:117-122.
11. Burns J., Yakota T., Ashihara H., Lean M.E.J., Crozier A. Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 2002, 50:3337-3340.
12. Cantó C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20:98-105.
13. V channels of beta cells. Eur. J. Pharmacol. 2007, 568:269-277.
14. Chi T.C., Chen W.P., Chi T.L., Kuo T.F., Lee S.S., Cheng J.T., Su M.J. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007, 80:1713-1720.
15. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
16. Das S., Alagappan V.K., Bagchi D., Sharma H.S., Maulik N., Das D.K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vasc. Pharmacol. 2005, 42:281-289.
17. de la Lastra C.A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans. 2007, 35:1156-1160.
18. Deng J.Y., Hsieh P.S., Huang J.P., Lu L.S., Hung L.M. Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways. Diabetes 2008, 57:1814-1823.
19. El-Mowafy A.M., Alkhalaf M. Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 2003, 24:869-873.
20. Feige J.N., Lagouge M., Canto C., Strehle A., Houten S.M., Milne J.C., Lambert P.D., Mataki C., Elliott P.J., Auwerx J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008, 8:347-358.
21. Fröjdö S., Cozzone D., Vidal H., Pirola L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 2007, 406:511-518.
22. Gnoni G.V., Paglialonga G. Resveratrol inhibits fatty acids and triacylglycerol synthesis in rat hepatocytes. Eur. J. Clin. Invest. 2009, 39:211-218.
23. Hambrock A., de Oliveira Franz C.B., Hiller S., Grenz A., Ackermann S., Schulze D.U., Drews G., Osswald H. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J. Biol. Chem. 2007, 282:3347-3356.
24. Hansen J.B., Arkhammar P.O., Bodvarsdottir T.B., Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr. Med. Chem. 2004, 11:1595-1615.
25. Hardie D.G., Pan D.A. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem. Soc. Trans. 2002, 30:1064-1070.
26. Henquin J.C. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000, 49:1751-1760.
27. Holloszy J.O., Fontana L. Caloric restriction in humans. Exp. Gerontol. 2007, 42:709-712.
28. Hung L.M., Chen J.K., Huang S.S., Lee R.S., Su M.J. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 2000, 47:549-555.
29. Juan M.E., Vinardell M.P., Planas J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28days is not harmful. J. Nutr. 2002, 132:257-260.
30. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'?. Eur. J. Endocrinol. 1998, 138:619-620.
31. Lagouge M., Argmann C., Grhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127:1-14.
32. Lee J.H., Song M.Y., Song E.K., Kim E.K., Moon W.S., Han M.K., Park J.W., Kwon K.B., Park B.H. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009, 58:344-351.
33. Li Z.D., Ma Q.Y., Wang C.A. Effect of resveratrol on pancreatic oxygen free radicals in rats wiyh severe acute pancreatitis. World J. Gastroenterol. 2006, 12:137-140.
34. Li Z.D., Ma Q.Y., Luo Y.H. Effect of resveratrol-induced FasL up-regulation on the apoptosis of pancreatic acinar cells in rats with severe acute pancreatitis. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29:454-457.
35. López-Lluch G., Irusta P.M., Navas P., de Cabo R. Mitochondrial biogenesis and healthy aging. Exp. Gerontol. 2008, 43:813-819.
36. Mayers J.R., Iliff B.W., Swoap S.J. Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction. FASEB J. 2009, 23:1032-1040.
37. Mishra R., Sellin D., Radovan D., Gohlke A., Winter R. Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol. ChemBioChem 2009, 10:445-449.
38. Palsamy P., Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 2008, 62:598-605.
39. Palsamy P., Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem. Biol. Interact. 2009, 179:356-362.
40. Park H.J., Yang J.Y., Ambati S., Della-Fera M.A., Hausman D.B., Rayalam S., Baile C.A. Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J. Med. Food 2008, 11:773-783.
41. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
42. Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik G., Menon V.P., Bagchi D., Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell. Mol. Med. 2008, 12:2350-2361.
43. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 2003, 17:1975-1985.
44. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschöp M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:9793-9798.
45. Pinent M., Castell A., Baiges I., Montagut G., Arola L., Ardévol A. Bioactivity of flavonoids on insulin-secreting cells. Comp. Rev. Food Sci. Food Safety 2008, 7:299-308.
46. Radovan D., Opitz N., Winter R. Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol. FEBS Lett. 2009, 583:1439-1445.
47. Ramadori G., Gautron L., Fujikawa T., Vianna C.R., Elmquist J.K., Coppari R. Central administration of resveratrol mproves diet-induced diabetes. Endocrinology 2009, 150:5326-5333.
48. Rayalam S., Della-Fera M.A., Yang J.Y., Park H.J., Ambati S., Baile C.A. Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J. Nutr. 2007, 137:2668-2673.
49. Rayalam S., Yang J.Y., Ambati S., Della-Fera M.A., Baile C.A. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother. Res. 2008, 22:1367-1371.
50. Rivera L., Morón R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
51. Rocha K.K., Souza G.A., Ebaid G.X., Seiva F.R., Cataneo A.C., Novelli E.L. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem. Toxicol. 2009, 47:1362-1367.
52. Rodgers J.T., Lerin C., Haas W., Gygi S.P., Spiegelman B.M., Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005, 434:113-118.
53. Schmatz R., Schetinger M.R., Spanevello R.M., Mazzanti C.M., Stefanello N., Maldonado P.A., Gutierres J., Corrêa Mde C., Girotto E., Moretto M.B., Morsch V.M. Effects of resveratrol on nucleotide degrading enzymes in streptozotocin-induced diabetic rats. Life Sci. 2009, 84:345-350.
54. Shang J., Chen L.L., Xiao F.X. Resveratrol improves high-fat induced nonalcoholic fatty liver in rats. Zhonghua Gan Zang Bing Za Zhi 2008, 16:616-619.
55. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29:698-706.
56. Sharma S., Anjaneyulu M., Kulkarni S.K., Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76:69-75.
57. Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 2008, 31:897-902.
58. Slater S.J., Seiz J.L., Cook A.C., Stagliano B.A., Buzas C.J. Inhibition of protein kinase C by resveratrol. Biochim. Biophys. Acta 2003, 1637:59-69.
59. Smith J.V., Heilbronn L.K., Ravussin E. Energy restriction and aging. Curr. Opin. Clin. Nutr. Metab. Care 2004, 7:615-622.
60. Steinberg G.R., Kemp B.E. AMPK in health and disease. Physiol. Rev. 2009, 89:1025-1078.
61. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:1339-1346.
62. Szkudelska K., Nogowski L., Szkudelski T. Resveratrol, a naturally occurring diphenolic compound affects lipogenesis, lipolysis and antylipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol. 2009, 113:17-24.
63. Szkudelska K., Nogowski L., Szkudelski T. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur. J. Clin. Invest. 2009, 39:899-905.
64. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur. J. Pharmacol. 2006, 55:176-181.
65. Szkudelski T. Resveratrol-induced inhibition of insulin secretion from rat pancreatic islets: evidence for pivotal role of metabolic disturbances. Am. J. Physiol. Endocrinol. Metab. 2007, 293:901-907.
66. Szkudelski T. The insulin-suppressive effect of resveratrol - an in vitro and in vivo phenomenon. Life Sci. 2008, 82:430-435.
67. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43:720-729.
68. Wang L., Ma Q., Chen X., Sha H., Ma Z. Effects of resveratrol on calcium regulation in rats with severe acute pancreatitis. Eur. J. Pharmacol. 2008, 580:271-276.
69. Yang J.Y., Della-Fera M.A., Rayalam S., Ambati S., Hartzell D.L., Park H.J., Baile C.A. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 2008, 82:1032-1039.
70. Zhang J. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 2006, 397:519-527.
71. Zhang Y., Jayaprakasam B., Seeram N.P., Olson L.K., DeWitt D., Nair M.G. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J. Agric. Food Chem. 2004, 52:228-233.